Chi Leung Chiang, Kenneth Sik Kwan Chan, Huaping Li, Wai Tong Ng, James Chung Hang Chow, Horace Cheuk Wai Choi, Ka On Lam, Victor Ho Fun Lee, Roger Kai Cheong Ngan, Anne Wing Mui Lee, Steven A Eschrich, Javier F Torres-Roca, Jason Wing Hon Wong
BACKGROUND: Locally advanced nasopharyngeal cancer (NPC) patients undergoing radiotherapy are at risk of treatment failure, particularly locoregional recurrence. To optimize the individual radiation dose, we hypothesize that the genomic adjusted radiation dose (GARD) can be used to correlate with locoregional control. METHODS: A total of 92 patients with American Joint Committee on Cancer / International Union Against Cancer stage III to stage IVB recruited in a randomized phase III trial were assessed (NPC-0501) (NCT00379262)...
April 16, 2024: Radiotherapy and Oncology